15th January 2019 | Galen Ltd, the Northern Ireland based pharmaceutical company, is delighted to announce the appointment of Dr Dennise Broderick as its new Managing Director and President. She will report to Alan Armstrong, CEO and Chairman, Almac Group, - the parent company of Galen Ltd.

Together with Almac Group’s Board of Directors, Dennise is responsible for all aspects of the pharmaceutical company’s operations, marketing and governance across its sites throughout Europe and the US.

Dennise is a highly successful, respected and inspiring Executive Business Leader, with an extensive career within the pharmaceutical industry. Most recently Dennise held the position of Country Manager, leading the Irish affiliate of IPSEN Pharmaceuticals and was responsible for all aspects of the business. Prior to this Dennise also held CEO/MD and senior leadership roles with Pfizer, Hospira, Zeneus, Viatris and other pharmaceutical companies both in Ireland and Europe.

Dennise is also very highly respected academically and remains on the invite list as a guest lecturer within the National Universities of Ireland having previously lectured part-time within their network.

Mr Armstrong, commented on Dennise’s appointment: “We are delighted to welcome Dennise to our team. Her inside knowledge of the industry will be instrumental in developing the Galen brand and growing the company globally. Her inspiring approach will be sure to help us meet our ambitious targets and look forward to an exciting future.”

Dr Broderick added, “It is an honour for me to join the Galen team and look forward to working with the established global management team to strengthen our vision to make Galen a successful global pharmaceutical company with a strong focus on both the customer and the patient. It’s an exciting challenge, one which I am looking forward to immensely.”

###

About Galen

Established in 1968, Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland), with products in therapy areas including gastroenterology, urology, female health, pain management and mental health.

As a subsidiary of Galen Limited, Galen US also has a growing presence in select conditions requiring topical anaesthesia and Central Nervous System disorders. The company plans to continue expanding its portfolio with selected products on an international basis. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value.

Visit: www.galen-pharma.com

About Almac Group

A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.

Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,000 highly skilled personnel across 17 facilities including Europe, the US and Asia. Click here to view our facilities.

We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.